[5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. A comparative randomized multicenter trial]
- PMID: 1526418
[5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. A comparative randomized multicenter trial]
Abstract
The therapeutic efficacy of 1 g 5-aminosalicylic acid enema was compared with that of 90 mg hydrocortisone acetate foam following daily rectal administration to patients with idiopathic proctitis or proctosigmoiditis during two weeks. A total of 199 patients (103 5-aminosalicylic acid, 96 hydrocortisone acetate) were included in a randomized, multicenter trial. Endoscopic and clinical remission was seen in 67 and 69 percent of the 5-aminosalicylic acid-treated and in 50 and 45 percent of the hydrocortisone acetate-treated patients (P less than 0.05), respectively. Mild side effects were seen in 10.7 percent of the 5-aminosalicylic acid-treated patients and in 3.1 percent of the hydrocortisone acetate-treated patients (P = 0.05). After 2 weeks, 5-aminosalicylic acid enemas are more effective than hydrocortisone foam for topical treatment of patients with idiopathic proctitis or proctosigmoiditis.
Similar articles
-
Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.Am J Gastroenterol. 2008 Dec;103(12):3106-14. doi: 10.1111/j.1572-0241.2008.02152.x. Am J Gastroenterol. 2008. PMID: 19086960 Clinical Trial.
-
Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.Ital J Gastroenterol Hepatol. 1999 Nov;31(8):677-84. Ital J Gastroenterol Hepatol. 1999. PMID: 10730559 Clinical Trial.
-
Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.Aliment Pharmacol Ther. 2006 Jan 15;23(2):303-12. doi: 10.1111/j.1365-2036.2006.02743.x. Aliment Pharmacol Ther. 2006. PMID: 16393311 Clinical Trial.
-
Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.Clin Pharm. 1992 Jun;11(6):514-28. Clin Pharm. 1992. PMID: 1600685 Review.
-
Topical salicylate therapy (4-ASA and 5-ASA enemas).Gastroenterol Clin North Am. 1989 Mar;18(1):35-42. Gastroenterol Clin North Am. 1989. PMID: 2563990 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources